WO2008001444A1 - Médicament adsorbant l'acide phosphorique à usage externe possédant un effet inhibiteur de croissance microbienne, produit contenant celui-ci et procédé de production de ce médicament - Google Patents

Médicament adsorbant l'acide phosphorique à usage externe possédant un effet inhibiteur de croissance microbienne, produit contenant celui-ci et procédé de production de ce médicament Download PDF

Info

Publication number
WO2008001444A1
WO2008001444A1 PCT/JP2006/312966 JP2006312966W WO2008001444A1 WO 2008001444 A1 WO2008001444 A1 WO 2008001444A1 JP 2006312966 W JP2006312966 W JP 2006312966W WO 2008001444 A1 WO2008001444 A1 WO 2008001444A1
Authority
WO
WIPO (PCT)
Prior art keywords
external preparation
ferrous
product
ferric hydroxide
production method
Prior art date
Application number
PCT/JP2006/312966
Other languages
English (en)
Japanese (ja)
Inventor
Tomotaka Yanagita
Koji Yamashita
Kotaro Kageyama
Original Assignee
Tomotaka Yanagita
Koji Yamashita
Kotaro Kageyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomotaka Yanagita, Koji Yamashita, Kotaro Kageyama filed Critical Tomotaka Yanagita
Priority to PCT/JP2006/312966 priority Critical patent/WO2008001444A1/fr
Priority to JP2006530827A priority patent/JP3995052B1/ja
Publication of WO2008001444A1 publication Critical patent/WO2008001444A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Definitions

  • Phosphate-adsorbing external preparation having microbial growth-inhibiting action, product containing the same, and method for producing the same
  • the present invention relates to a phosphate-adsorbing external preparation having a microbial growth inhibitory action. Specifically, the present invention relates to an external preparation that is applied to human bodies to suppress the growth of microorganisms and an external preparation that is applied to objects to suppress the growth of microorganisms.
  • microbial growth inhibitors antibacterial agents
  • a coating composition containing a microbial growth inhibitor that exhibits antibacterial, antifungal and antialgal properties has been proposed in order to give a product a microbial growth inhibitory action.
  • examples of conventional organic microbial growth inhibitors include thiophene compounds, isothiazoline compounds, organic iodine compounds, and antibiotics (Patent Document 1), and inorganic microbial growth inhibitors.
  • the agent include titanium oxide thin films (Non-patent Document 1).
  • Patent Document 1 JP 2002-114946
  • Non-Patent Document 1 Optical Clean Revolution Akira Fujishima et al. (Issued by CMC Co., Ltd.) Invention Disclosure
  • the present inventors firstly indirectly change the environment, which is difficult to grow, by using a type of antibacterial agent that works directly on the fungus and kills the fungus as in the conventional antibacterial agent. Furthermore, an antibacterial agent of a type that suppresses the growth of the bacterium (specifically, a type that suppresses the growth of the bacterium by cutting off the nutrient source of the bacterium) was examined. As a result, it has also been found that certain iron compounds have a phosphorus adsorption effect sufficient to suppress the growth of bacteria and have excellent biological safety, and the present invention (1) to (26) Was completed.
  • the present invention (1) is an external preparation characterized by containing ferric hydroxide produced under conditions where ferrous species are present.
  • the alkali is removed.
  • External use of the invention (1) produced by adjusting the pH to 1.5 to 5.5 (preferably 1.5 to 4.0, more preferably 2.0 to 3.5) It is an agent.
  • the ferric hydroxide has an oxidation-reduction potential as an oxidizing agent in a ferrous aqueous solution.
  • the ferric hydroxide contains an oxidizing agent in a ferrous aqueous solution in an amount less than an equivalent amount of ferrous iron and has a redox potential of +400 to 770 mV (preferably Is +500 to 730 mV, more preferably +600 to 700 mV), and the pH at the end of the reaction is 1.5 to 5.5 (preferably 1.5 to 4.0, more preferably ⁇ ) by adding alkali.
  • This is an external preparation of the invention (1) produced by adjusting to 2.0 to 3.5).
  • the present invention (5) is the external preparation according to any one of the inventions (2) to (4), wherein the oxidizing agent is hypochlorite.
  • the present invention (6) is the external preparation according to any one of the inventions (1) to (5), wherein the ferric hydroxide is amorphous.
  • the present invention (7) is the external preparation according to any one of the inventions (1) to (6), further comprising glycerin.
  • the present invention (8) is the external preparation according to any one of the inventions (1) to (7), which is phosphate ion adsorptive.
  • the present invention (9) is the external preparation according to any one of the inventions (1) to (8) having a microbial growth inhibitory action.
  • the present invention (10) is an external preparation according to any one of the inventions (1) to (9) for application to a human or animal body.
  • the present invention (11) is the external preparation according to any one of the inventions (1) to (9) for application to a product.
  • the present invention (12) is a product containing any one of the external preparations of the inventions (1) to (11).
  • the present invention (13) is the product of the invention (12), which is a human or animal hygiene product, a human or animal medical product, a pharmaceutical product, a quasi-drug, a cosmetic product or a daily product.
  • the present invention (14) includes a diaper or diaper sheet, a sanitary product (napkin or tampon), a panty liner or panty sheet, an incontinence pad, a pet paper diaper, a pet sanitary product, a mask, a sweat pad, a breast milk pad,
  • an oxidant is added to a ferrous aqueous solution in an amount less than the equivalent amount of ferrous iron, and then anoleic acid is removed from pHl. 5 to 5.5 (preferably 1. 5 to 4.0, more preferable [0,3,5,5) [Method of producing an external preparation containing ferric hydroxide, characterized by including a step of adjusting to such a degree. It is.
  • an oxidizing agent is added to a ferrous aqueous solution so that the redox potential is +400 to 770 mV (preferably +500 to 730 mV, more preferably +600 to 700 mV).
  • the pressure adjust the pressure so that it is pHl. 5 to 5.5 (preferably ⁇ 1.5 to 4.0, more suitable [2.5 to 3.5]). It is a manufacturing method of the external preparation containing ferric hydroxide characterized by including the process to do.
  • an oxidizing agent is added to a ferrous aqueous solution in an amount less than the equivalent of ferrous iron, so that the acid reduction potential is +400 to 770 mV (preferably +500 to 730 mV, More suitable ⁇ KO ⁇ MA + 600 ⁇ 70
  • a method for producing an external preparation containing ferric hydroxide comprising a step of adjusting to 0 to 3.5).
  • the present invention (18) is the production method of any one of the inventions (15) to (17), wherein the oxidizing agent is hypochlorite.
  • the present invention (19) is the production method of any one of the inventions (15) to (18), wherein the ferric hydroxide is amorphous.
  • the present invention (20) is the production method of any one of the inventions (15) to (19), further comprising a step of adding glycerin.
  • the present invention (21) further includes a step of dehydration, freeze drying or spray drying.
  • the present invention (22) includes the step of adding glycerin after the pH adjustment step, before the dehydration, freeze-drying or spray-drying step, or at or after the step. It is a manufacturing method.
  • the present invention (23) is the manufacturing method of any one of the inventions (15) to (22), wherein the external preparation is phosphate ion adsorptive.
  • the external preparation has a microbial growth inhibitory action. 23)! Is one of the manufacturing methods.
  • the present invention (25) is the production method according to any one of the inventions (15) to (24), wherein the external preparation is applied to a human or animal body.
  • the external preparation is applied to a product.
  • Ferous ferrous species refers to substances in which iron is present in a divalent state, such as ferrous iron and ferrous compounds (eg, ferrous hydroxide).
  • the “ferrous iron aqueous solution” is not particularly limited as long as it is an aqueous solution containing ferrous ions, and may contain other substances.
  • ⁇ External preparation '' is not limited to ⁇ external preparation '' in the narrow sense related to pharmaceuticals, quasi drugs, and cosmetics, but it is applied to the surface and Z or inside of products in addition to those applied to the human body. It is a concept including what is done.
  • Oxidizing agent is not particularly limited, and examples thereof include hypochlorite, hydrogen peroxide, calcium, and id peroxide, and hypochlorite is preferable.
  • Microorganism is a concept that includes bacteria and sputum.
  • antibacterial as used in the present invention is the result of suppressing the growth of bacteria on the surface of animals (including humans) and objects, and “sterilization”, “sterilization”, “disinfection”, “antibacterial”. ”,“ Bacteriostatic ”,“ antifungal ”,“ antiseptic ”and the like.
  • This external preparation contains, as an active ingredient, amorphous ferric hydroxide produced under the condition where ferrous species (for example, hydrated ferrous hydroxide) are present.
  • the active ingredient is characterized by having a high phosphorus adsorption capacity (phosphate absorption capacity). Due to its nature, when applied to animals (including humans) and products as an external preparation, the amount of phosphorus, which is an essential nutrient, is significantly reduced from the application target, resulting in a microbial growth inhibitory effect in the application target. It is a mechanism. In this way, this drug suppresses the growth of microorganisms by removing phosphorus, which is an essential nutrient for the biological activities of microorganisms, and tries to solve the above problems. None give.
  • the active ingredient exhibiting high phosphorus adsorption ability is amorphous hydroxide and ferric iron. If it is ferric iron, it does not have the effect.
  • hydroxide and ferric hydroxide produced by adding caustic soda to ferric solution and commercially available hydroxide and ferric hydroxide do not show a high phosphorus adsorption capacity (see Examples).
  • This ferric hydroxide is an Eh (oxidation-reduction battery) in the Fe 2+ -Fe (OH) system.
  • ferrous hydroxide contained in the produced precipitate contained ferrous hydroxide, and it was unstable and extremely amorphous. Therefore, the Fe-0-Fe-O-Fe- bond is unstable and can be easily broken! /.
  • This ferric hydroxide has the properties of the newly formed Fe-OH group while breaking the bond. It is presumed that it reacts with phosphate ions, etc. to show a remarkably high adsorption power.
  • the chemical structure of the ferric hydroxide ferric iron is not clear, but based on the experimental results, it is presumed that it is the following structure (however, the ferric hydroxide ferric acid of the present invention is However, the present invention is not limited to the estimated form). That is, the ferric hydroxide essentially contains ferric iron, and an oxygen atom or a hydroxyl group is six-coordinated to the iron atom, and the six-coordinate iron is linked through the oxygen atom. It is estimated that Then, it is presumed that a certain type of water molecule present around the iron atom is destabilizing the bond as a result of affecting the bond between the iron atom and the oxygen atom.
  • the preferred form is one in which Fe-0-Fe-0-Fe (clusters) are of an appropriate size due to the presence of appropriate hydroxyl groups.
  • amorphous and “very high degree of amorphous” mean that the 20 value in the powder X-ray diffraction using Cu ⁇ ⁇ -ray as an X-ray source is 5 ° to 80 °. It has at least one amorphous halo figure in the range of °, which means that there is no obvious crystalline peak. In addition, a slight crystalline peak may be observed in the amorphous halo figure depending on the starting material at the time of manufacture. In such a case, powder X-ray diffraction using Cu K-wire as an X-ray source is possible.
  • the crystallinity peak intensity observed in the range of 20 ° to 80 ° with a 20 value is 5% or less in terms of the ratio of the corresponding crystalline reference substance to the crystalline peak (% X-ray diffraction intensity Z reference substance). If it is.
  • % X-ray diffraction intensity Z reference material those given by the following formula in accordance with ASTM (American Society for Testing and Materials) D3906 can be used.
  • the number of crystalline peaks used for calculating the integrated reflection intensity is not particularly limited, but a range of 1 to 8 is preferable.
  • the active ingredient is hydroxide and ferric iron, it is unavoidable because it is produced under the condition that ferrous species (for example, ferrous hydroxide) exist as described above.
  • ferrous species for example, ferrous hydroxide
  • the content of ferrous ferrous species is not particularly limited, but it is usually 5% by weight or less based on the dry weight (furnace dry, 105 ° C, 2h). Is from 0.01 to 4% by weight, more preferably from 0.1 to 2% by weight.
  • ferrous species are inevitably contained in this way, but the components may be removed by washing.
  • the external preparation is crystalline as long as amorphous ferric hydroxide as an active ingredient is present. May contain high-quality hydroxide and ferric iron.
  • the amorphous component is preferably 30% or more, more preferably 50% or more, and further preferably 75% or more.
  • the external preparation further contains glycerin.
  • ferric hydroxide binds to the iron of Fe—0—Fe—0—Fe! /, The OH group dehydrates, and the cluster becomes large. It may change to a stable state and the adsorption power may decrease. Therefore, for example, by mixing glycerin with wet ferric hydroxide and ferric hydroxide, dehydration of OH groups is difficult to occur even when dried, so that a decrease in adsorptive power can be remarkably suppressed.
  • the content of glycerin is preferably 20% by weight or less based on the dry weight (furnace dry, 105 ° C., 2 h).
  • an oxidizing agent for example, hypochlorite aqueous solution
  • a ferrous aqueous solution below the equivalent of ferrous iron (preferably 0.3 to 0.95, more preferably 0). 4 to 0.8)
  • an oxidizing agent for example, hypochlorite aqueous solution
  • ferrous aqueous solution with a redox potential of +400 to 770 mV
  • alkali preferably caustic pHl. 5 To 5.5 (preferably 1.5 to 4.0, more preferably 2.0 to 3.5).
  • the order of (Step 1A) or (Step 1B) and (Step 2) is important. If reversed, an external preparation having a high phosphorus adsorption capacity cannot be obtained.
  • each condition will be described.
  • the ferrous salt that can be used in the ferrous aqueous solution is not particularly limited as long as it is a water-soluble salt, and examples thereof include ferrous sulfate, ferrous chloride, and ferrous nitrate.
  • ferrous sulfate is preferred because it allows easy filtration of the precipitate.
  • concentration of ferrous ions in the ferrous aqueous solution is preferably 0.05 to 2M.
  • the usable oxidizing agent is not particularly limited, but is preferably hypochlorite.
  • examples of the hypochlorite include sodium hypochlorite and calcium hypochlorite, and sodium hypochlorite is particularly preferable.
  • the hypochlorite concentration in the hypochlorite aqueous solution is not particularly limited, but commercially available 5 to 10% can be used.
  • the amount of the oxidizing agent to be used is changed to the ferrous aqueous solution.
  • the amount is less than the equivalent of ferrous iron in the liquid.
  • the amount of the oxidizing agent is preferably 0.3 to 0.95 force S in terms of equivalent ratio to the amount of ferrous iron, and more preferably 0.4 to 0.8.
  • an oxidizing agent for example, a hypochlorite aqueous solution
  • the oxidation-reduction potential is +400 to 770 mV (preferably +500 to 730 mV, More preferably, it is added to +600 to 700 mV.
  • an oxidizing agent solution for example, hypochlorite aqueous solution
  • Step 1A and Step 1B are not necessarily mutually independent steps, and if Step 1A is performed, Step 1B will be performed as a result and vice versa. To do.
  • step 2 of adding an alkali is performed.
  • the alkali is not particularly limited, but is preferably a caustic alkali.
  • the caustic alkali include caustic soda and caustic potassium, and caustic soda is preferable.
  • the alkali concentration (preferably caustic concentration) is, for example, 0.5 to 5N.
  • an alkaline aqueous solution (preferably a caustic aqueous solution) is added to a solution to which a predetermined amount of oxidizing agent is added (step 1A) or a solution in which the oxidation-reduction potential is within the above range (step 1B).
  • Adjust to pHl. 5 to 5.5 (preferably ⁇ 1.5 to 4.0, more suitable 2.0 to 3.5).
  • the external preparation is preferably in a dry form for handling.
  • dehydration, freeze-drying or spray-drying is suitable as the drying method. According to these methods, the phosphate adsorption capacity is kept high because there is little dehydration from the Fe-sodium bond during drying.
  • the addition amount of glycerin is 20% or less (preferably 3 to 7%) with respect to the dry weight (furnace dry, 105 ° C., 2 h).
  • the timing of mixing glycerin is not particularly limited, but is preferably after pH adjustment and before drying.
  • This topical agent can be applied to any target that is required to suppress the growth of microorganisms such as fungi and the like, for example, animals (including humans) and products.
  • the application areas of the external preparation are mainly in the fields of industry, life and medicine.
  • Specific application fields in the industrial field include, for example, a paper / pulp slime control agent, a wood preservative field, a water treatment field, and a separation field.
  • Specific fields of use in daily life include household appliances such as refrigerators, washing machines, water purifiers, humidifiers, vacuum cleaners and dust filters, toilets, baths, toilets, etc. This includes the kitchenware field, sanitary napkins, toiletries such as toothbrushes, and stationery such as pencils.
  • Specific fields of use in the medical field include textiles such as lab coats and curtains in hospitals, medical equipment such as wallpaper, building materials, and plastics.
  • typical use modes for direct application to human animals are pharmaceutical, quasi-drug or cosmetic use modes.
  • a dosage form such as a solubilizing system such as lotion, an emulsifying system such as cream or emulsion, a dispersion system such as calamine lotion, or an aerosol filled with a propellant.
  • drugs, moisturizers, UV absorbers, thickeners, soluble glazes, detergents, emulsifiers, fats and oils which are usually blended in pharmaceuticals, quasi drugs or cosmetics.
  • products of the use mode human or animal drugs, quasi drugs or cosmetics can be mentioned. More specifically, examples include a millet external preparation, an anti-odor agent, baby powder, and an antibacterial spray.
  • examples of the product include a human or animal hygiene product, a human or animal medical product, or a living product.
  • a typical application mode is that the external preparation is applied to the surface of the object, or the external preparation is applied to the inside of the object (for example, when the object is fibrous, the external agent is applied between the fibers. And, if the product is in the form of greaves, the external preparation is dispersed in the greaves).
  • an external preparation is applied to the surface or inside of the product, but the present invention is not limited to this.
  • an antibacterial treatment such as an antibacterial spray or a garbage deodorant is performed.
  • Products for applying antibacterial treatment to products that have not been used can also be mentioned as specific examples of this external preparation.
  • the applied amount is 20 to 200 g per lm 2 of the surface area of the animals or products. It is preferable.
  • this topical agent when used as a pharmaceutical, quasi-drug or cosmetic, it may be applied to the product as needed and when applied to the product, This antibacterial film is formed by mixing a product raw material (for example, rosin, prepolymer, monomer) with the external preparation, or by mixing it with a polymer having various film forming properties. You can apply a functional film to the product.
  • a product raw material for example, rosin, prepolymer, monomer
  • 1N caustic soda was added to the solution until the pH was stabilized at 2.7 to obtain an external preparation according to this example.
  • the pH at the end of the reaction was 2.7 and the redox potential was +584 mV.
  • Phosphorus absorption capacity was measured by taking 0.5 g of the external preparation according to this example in a dry weight of 0.5 g of ammonium phosphate solution (5.9 g of PZD 20 ml) and leaving it for 24 hours with occasional shaking. Then, this was filtered and the phosphorus concentration of the filtrate was measured and calculated.For comparison, the hydroxide produced by rapidly stirring IN NaOH to pH 7.5 to 8.0 in lMFeC 1 aqueous solution.
  • E.coli ATCC 25922 E. coli Gram-negative bacteria
  • P.aeruginosa ATCC27853 Pseudomonas aeruginosa-Gram-negative bacteria
  • a topical preparation dry weight
  • a topical preparation dry weight
  • a mixture not mixed for comparison a topical preparation (dry weight) 2.5 gZl00ml ⁇
  • a mixture not mixed for comparison Prepared.
  • the above three strains were cultured as representatives of bacteria causing problems in clinical medicine under the joint conditions of the examples and comparative examples, and the degree of antibacterial properties of the external preparations according to the examples was observed.
  • the results are shown in the table.
  • the antibacterial property was judged by the number of bacterial colonies grown on each medium.
  • the evaluation criteria are “+++” with a very large number of colonies, “+” with a small number of colonies, “++” between +++ and +, and “one” with colonies.
  • the external preparation according to the example has a growth inhibitory effect (static antibacterial property) in both gram-positive and gram-negative bacteria.
  • the Gram-positive bacteria mentioned above refers to those that are colored purple by Gram staining, and the Gram-negative bacteria are those that are colored red by Gram staining.
  • the test was conducted on 30 men and women (15 people per group) who suffered from millet from 15 to 25 years old.
  • the test method was to clean the face thoroughly with cosmetic soap, then apply the above-mentioned topical millet preparation twice a day (morning and wrinkle) on the millet, and then use a moisturizing adhesive bandage to prevent drying. Adopted the method of coating with, and after one month, the appearance of millet was evaluated.
  • the evaluation criteria were performed in two stages: (A) the symptom was improved compared to before application, and (B) the symptom was unchanged or deteriorated compared to before application. As a result, (A) evaluation was 23 out of 30 persons, and (B) evaluation was 7 persons (7 out of 7 persons were unchanged). In addition, no adverse effects on the skin due to the application of this drug were confirmed.
  • An antibacterial layer was formed by spraying a mixture of the external preparation and water according to this example (external preparation 1 mass%) at a rate of 150 gZm 2 on a thick nylon mat material. Then, in order to confirm the effect of the mat material dried until the water evaporates, a mold resistance test was conducted by a test method according to JISZ-29110000. For comparison, a similar test was performed on a mat material without an antibacterial layer. The evaluation criteria are 0: no mold on the test sample, 1: mold on the test sample does not exceed 1Z3, 2: mold on the test sample exceeds 1Z3.
  • the mat material without antibacterial treatment produced a large amount of ringworms (evaluation: 2), whereas the mat material with antibacterial treatment did not show the occurrence of ringworms. (Evaluation: 0). Therefore, if the topical agent is applied to the mat material, the athlete's foot holder will use the mat. Even in this case, it was confirmed that the athlete's foot can be prevented from infecting others.
  • FIG. 1 is an X-ray diffraction measurement chart of Sample No. 1.
  • Figure 2 is an X-ray diffraction measurement chart of Sample No. 1.
  • FIG. 3 is an X-ray diffraction measurement chart of Sample No. 2.
  • FIG. 4 is an X-ray diffraction measurement chart of Sample No. 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un médicament à usage externe qui est hautement stable in vivo, qui peut être produit à faible coût et qui possède un effet inhibiteur de croissance microbienne. Ce médicament se caractérise ce qu'il contient comme principe actif un hydroxyde ferrique amorphe produit en présence d'un hydroxyde ferreux.
PCT/JP2006/312966 2006-06-29 2006-06-29 Médicament adsorbant l'acide phosphorique à usage externe possédant un effet inhibiteur de croissance microbienne, produit contenant celui-ci et procédé de production de ce médicament WO2008001444A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2006/312966 WO2008001444A1 (fr) 2006-06-29 2006-06-29 Médicament adsorbant l'acide phosphorique à usage externe possédant un effet inhibiteur de croissance microbienne, produit contenant celui-ci et procédé de production de ce médicament
JP2006530827A JP3995052B1 (ja) 2006-06-29 2006-06-29 微生物増殖抑制作用を有するリン酸吸着性外用剤、それを含有する製品及びその製造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2006/312966 WO2008001444A1 (fr) 2006-06-29 2006-06-29 Médicament adsorbant l'acide phosphorique à usage externe possédant un effet inhibiteur de croissance microbienne, produit contenant celui-ci et procédé de production de ce médicament

Publications (1)

Publication Number Publication Date
WO2008001444A1 true WO2008001444A1 (fr) 2008-01-03

Family

ID=38683370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/312966 WO2008001444A1 (fr) 2006-06-29 2006-06-29 Médicament adsorbant l'acide phosphorique à usage externe possédant un effet inhibiteur de croissance microbienne, produit contenant celui-ci et procédé de production de ce médicament

Country Status (2)

Country Link
JP (1) JP3995052B1 (fr)
WO (1) WO2008001444A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012167050A (ja) * 2011-02-14 2012-09-06 Sumitomo Seika Chem Co Ltd 水溶性架橋剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112076215A (zh) * 2020-08-18 2020-12-15 珠海市索利达医疗器械有限公司 一种改善生殖道微生态的抗菌组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186919A (ja) * 1983-01-24 1984-10-23 ザ，プロクタ−，エンド，ギヤンブル，カンパニ− オムツかぶれおよびオムツ皮膚炎を治療しかつ予防する方法
JP2001158743A (ja) * 1999-12-02 2001-06-12 Wakamoto Pharmaceut Co Ltd 乳酸菌含有組成物、医薬及び食品
JP2004161642A (ja) * 2002-11-12 2004-06-10 Tadashi Inoue 無機系抗菌剤を含有してなる貼付剤、軟膏、噴霧剤等の皮膚用薬
JP2005021446A (ja) * 2003-07-03 2005-01-27 Tadashi Inoue 吸水性物品

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186919A (ja) * 1983-01-24 1984-10-23 ザ，プロクタ−，エンド，ギヤンブル，カンパニ− オムツかぶれおよびオムツ皮膚炎を治療しかつ予防する方法
JP2001158743A (ja) * 1999-12-02 2001-06-12 Wakamoto Pharmaceut Co Ltd 乳酸菌含有組成物、医薬及び食品
JP2004161642A (ja) * 2002-11-12 2004-06-10 Tadashi Inoue 無機系抗菌剤を含有してなる貼付剤、軟膏、噴霧剤等の皮膚用薬
JP2005021446A (ja) * 2003-07-03 2005-01-27 Tadashi Inoue 吸水性物品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAGUCHI T. ET AL.: "Glucosamine Tenka ni yoru Muteikei Suisankatetsu no Gosei to Keiko Phosphorus Kyuchakuzai to Shiteno Hyoka", DAI 72 KAI CSJ: THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU, 1997, pages 1271 + ABSTR. NO. 4K107, XP003019894 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012167050A (ja) * 2011-02-14 2012-09-06 Sumitomo Seika Chem Co Ltd 水溶性架橋剤

Also Published As

Publication number Publication date
JPWO2008001444A1 (ja) 2009-11-26
JP3995052B1 (ja) 2007-10-24

Similar Documents

Publication Publication Date Title
KR970000745B1 (ko) 항균성 화장료용 안료와 그 제조방법 및 이를 함유하는 화장료 조성물
CN108064152B (zh) 包含氧基-氢氧化铜纳米颗粒的抗菌组合物及其作为杀生剂的用途
US20090148540A1 (en) Antibacterial composition and method of production
TW201505639A (zh) 抗微生物之組成物及其製造方法
JP5892583B2 (ja) 抗菌用銀イオン生成液、その液から生成された銀イオン抗菌液及びその抗菌液を生成する生成方法
CH701627B1 (de) Verfahren zur Herstellung einer Zusammensetzung von Hypochlorsäure und deren Anwendungen.
DE202006018695U1 (de) Stoff mit antimikrobieller Wirkung
CN105377749A (zh) 掺杂的金属氧化物纳米颗粒和其用途
WO2014133149A1 (fr) Procédé de production d'un liquide antibactérien à base d'ions argent, liquide antibactérien à base d'ions argent produit par ledit procédé et produit à base d'ions argent contenant ledit liquide antibactérien
JP2001505237A (ja) 不快な臭気を発散しない衛生製品用超吸収性組成物
EP0920252A1 (fr) Compositions antimicrobiennes a base d'argent
EP4057814A1 (fr) Composites polymères antimicrobiens et antiviraux, biologiquement actifs efficaces contre le sras-cov-2 et d'autres cibles virales, bactériennes et fongiques, ainsi que procédés, matériaux, revêtements et dispositifs associés
EP2389419A1 (fr) Revêtements antimicrobiens
JP3529059B2 (ja) 抗菌消臭剤
JP3995052B1 (ja) 微生物増殖抑制作用を有するリン酸吸着性外用剤、それを含有する製品及びその製造方法
Zhou et al. Evaluation of antithrombogenic and antibacterial activities of a graphite oxide/heparin–benzalkonium chloride composite
JP4413465B2 (ja) 銀系抗菌剤
RU2446810C2 (ru) Антимикробные агенты
US20040214809A1 (en) Stabilized silver-ion sulfite complex compositions and methods
JP3300085B2 (ja) 吸着性組成物およびその製造法
Haustein et al. Growth inhibition of coryneform bacteria by a mixture of three natural products-Farnesol, glyceryl monolaurate, and phenoxyethanol: HGQ
JP2006199659A (ja) 消臭兼制汗剤
JPH10194929A (ja) 化粧料用抗菌性顔料、前記顔料の製造方法及び前記顔料を含有する化粧料組成物
US11000502B2 (en) Antimicrobial compositions comprising copper-hydroxypyrone complexes
KR20030008048A (ko) 항균소취제를 함유하는 일회용 흡수제품

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006530827

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06767583

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06767583

Country of ref document: EP

Kind code of ref document: A1